WO2023178169 - COMPOSITIONS AND METHODS FOR TREATING THE PATHOPHYSIOLOGY OF SEVERE VIRAL INFECTION
National phase entry is expected:
Publication Number
WO/2023/178169
Publication Date
21.09.2023
International Application No.
PCT/US2023/064419
International Filing Date
19.04.2023
Title **
[English]
COMPOSITIONS AND METHODS FOR TREATING THE PATHOPHYSIOLOGY OF SEVERE VIRAL INFECTION
[French]
COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA PATHOPHYSIOLOGIE D'UNE INFECTION VIRALE GRAVE
Applicants **
ANEMOI BIOTECH HOLDINGS, INC.
XU, Jian Qing
MANDELL, Robert
LUBIT, Beverly W.
Inventors
XU, Jian Qing
MANDELL, Robert
LUBIT, Beverly W.
Priority Data
63/320,119
15.03.2022
US
63/371,303
12.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5318 | |
| EPO | Filing, Examination, Granting | 36226 | |
| Japan | Filing, Examination, Granting | 3143 | |
| South Korea | Filing, Examination, Granting | 4297 | |
| USA | Filing, Examination, Granting | 11960 |
Total:
60,944
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
According to one aspect the described invention provides a method for reducing damaging effects of a severe virus infection in a susceptible subject comprising administering a pharmaceutical composition comprising a vehicle and a recombinant bifunctional fusion protein comprising a recombinant biologically active immunomodulatory component operatively linked to a recombinant biologically active anti-viral component, the recombinant immunomodulatory component comprising a recombinant biologically active human trefoil protein molecule, fragment or variant and the recombinant anti-viral component comprising a recombinant biologically active human interferon molecule, fragment or variant, wherein the method rescues symptoms of the severe virus infection.[French]
Selon un aspect, l'invention décrite concerne une méthode de réduction des effets néfastes d'une infection virale grave chez un sujet sensible comprenant l'administration d'une composition pharmaceutique comprenant un véhicule et une protéine de fusion bifonctionnelle recombinante comprenant un composant immunomodulateur biologiquement actif recombinant lié de manière fonctionnelle à un composant antiviral biologiquement actif recombinant, le composant immunomodulateur recombinant comprenant une molécule, un fragment ou une variante de protéine en trèfle humaine biologiquement active recombinante et le composant antiviral recombinant comprenant une molécule, un fragment ou une variante d'interféron humain biologiquement actif recombinant, ladite méthode soulageant les symptômes de l'infection virale grave.